Connect with us

Hi, what are you looking for?

Jewish Business News


Clal Biotech Suing Hyperion for $200 Million over ‘Rash and Ill Considered’ Andromeda Decisions

Reuven Krupik

Clal Biotechnology Industries Ltd. (TASE: CBI announced yesterday that it had filed a $200 million suit against drug company Hyperion Therapeutics Inc. (Nasdaq: HPTX) in the US in the State of Delaware Court, citing decisions by Hyperion that it alleges were “commercially unreasonable, rash and ill-considered, and were not based on careful analysis of the alternatives.”

Hyperion acquired Andromeda Biotech, which was developing Type 1 (juvenile) diabetes drug DiaPep277, in June, after several months of stringent professional examinations. But on September 8, Hyperion announced that it was halting development of Andromeda’s drug after claiming that the Israeli company’s employees had falsified clinical trial results. Following that announcement, Clal Biotechnology’s share plunged, and the company announced it was writing off NIS 506 million.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

On Sunday, Clal Biotechnology, whose CEO is Reuven Krupik, announced that it had contacted Hyperion in order to obtain documents and information backing up its claims. Clal Biotechnology and Hyperion representatives met in the US.

Clal Biotechnology says in its statement of claim that Hyperion’s decision to halt development of the drug was unreasonable “even if there is a basis for Hyperion’s allegations concerning the alleged misconduct by certain Andromeda employees and its external research advisor.”

Clal Biotechnology points out that it agreed to accept from Hyperion a relatively low upfront payment at the time of the sale of Andromeda, with the remainder in the form of contingent payments based on milestones and sales. “Therefore, ” Clal Biotechnology alleges, “Hyperion’s breach of the share purchase agreement and conduct have caused substantial damage to CBI (which was reflected by a sharp drop in its market capitalization), other stakeholders and the future of the drug.”

Published by Globes [online], Israel business news –



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.